{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:02:21Z","timestamp":1748059341165,"version":"3.41.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Melanoma is a leading cause of cancer-related deaths and is frequently driven by mutations in the BRAF and NRAS genes. These mutations disrupt key cellular signalling pathways that promote tumour growth and metastasis, but they have distinct biological and clinical implications, particularly in their response to treatment and impact on patient prognosis. The epithelial\u2013mesenchymal transition (EMT) is a process in which epithelial cells undergo changes in response to specific transcription factors. There are currently few studies investigating the EMT within BRAF and NRAS mutations. The aim of this study was to further elucidate activation of the EMT pathway in metastatic melanoma, focusing on BRAF- and NRAS-mutated samples from The Cancer Genome Atlas. Gene Set Enrichment Analysis revealed that BRAF mutations were more significantly associated with increased EMT activation relative to all other mutations in the dataset. In contrast, NRAS mutations were not significantly associated with gene expression of the EMT pathway, suggesting alternative mechanisms for metastasis.<\/jats:p>","DOI":"10.1093\/ced\/llaf023","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:32:32Z","timestamp":1736965952000},"page":"1180-1182","source":"Crossref","is-referenced-by-count":0,"title":["Differential gene set enrichment of the epithelial\u2013mesenchymal transition pathway in <i>BRAF-<\/i> vs. <i>NRAS<\/i>-mutated metastatic melanoma"],"prefix":"10.1093","volume":"50","author":[{"given":"Victor J","family":"Raimundi-Santos","sequence":"first","affiliation":[{"name":"School of Medicine, Medical Sciences Campus, University of Puerto Rico , San Juan, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1413-2100","authenticated-orcid":false,"given":"Tyrel R","family":"Porter","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Caribe , Bayam\u00f3n, Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025052303174021900_llaf023-B1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"2025052303174021900_llaf023-B2","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.3390\/cells10092320","article-title":"Molecular markers and targets in melanoma","volume":"10","author":"Teixido","year":"2021","journal-title":"Cells"},{"key":"2025052303174021900_llaf023-B3","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/cancers12082154","article-title":"EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment","volume":"12","author":"Tang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025052303174021900_llaf023-B4","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052303174021900_llaf023-B5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"2025052303174021900_llaf023-B6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2025052303174021900_llaf023-B7","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2025052303174021900_llaf023-B8","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.3390\/cancers15235521","article-title":"Exploring the in vitro and in vivo therapeutic potential of BRAF and MEK inhibitor combination in NRAS-mutated melanoma","volume":"15","author":"Niessner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025052303174021900_llaf023-B9","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","article-title":"NRAS mutant melanoma: towards better therapies","volume":"99","author":"Randic","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025052303174021900_llaf023-B10","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2147\/OTT.S117121","article-title":"NRAS-mutant melanoma: current challenges and future prospect","volume":"10","author":"Mu\u00f1oz-Couselo","year":"2017","journal-title":"OncoTargets Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf023\/61444608\/llaf023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1180\/61444608\/llaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/6\/1180\/61444608\/llaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:17:51Z","timestamp":1747984671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/6\/1180\/7954654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf023","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,15]]}}}